Spruce Biosciences (SPRB) to Release Earnings on Tuesday

Spruce Biosciences (NASDAQ:SPRB) is projected to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Spruce Biosciences to post earnings of ($7.9340) per share for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Spruce Biosciences (NASDAQ:SPRB) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($9.58) EPS for the quarter, missing analysts’ consensus estimates of ($9.16) by ($0.42). On average, analysts expect Spruce Biosciences to post $-31 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Spruce Biosciences Stock Performance

Shares of SPRB opened at $57.28 on Monday. Spruce Biosciences has a 52 week low of $4.35 and a 52 week high of $240.00. The stock has a market capitalization of $78.47 million, a price-to-earnings ratio of -1.11 and a beta of 3.26. The stock has a fifty day moving average of $60.93 and a 200-day moving average of $82.24.

Institutional Trading of Spruce Biosciences

Large investors have recently bought and sold shares of the business. SkyView Investment Advisors LLC acquired a new stake in Spruce Biosciences during the 4th quarter worth about $261,000. State Street Corp acquired a new stake in Spruce Biosciences during the 4th quarter worth about $558,000. Superstring Capital Management LP acquired a new stake in Spruce Biosciences during the 4th quarter worth about $1,057,000. Geode Capital Management LLC acquired a new stake in Spruce Biosciences during the 4th quarter worth about $1,109,000. Finally, Caligan Partners LP acquired a new stake in Spruce Biosciences during the 4th quarter worth about $1,787,000. 91.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Citizens Jmp dropped their price target on Spruce Biosciences from $180.00 to $170.00 and set a “market outperform” rating for the company in a research note on Tuesday, March 10th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Spruce Biosciences in a research note on Tuesday, March 10th. Finally, Craig Hallum began coverage on Spruce Biosciences in a report on Monday, April 27th. They issued a “buy” rating and a $140.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $190.60.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.